EffRx Pharmaceuticals announced the FDA has accepted its New Drug Application (NDA) for the company’s lead development program EX101. EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

The EX101 formulation is the first and only effervescent bisphosphonate alternative to tablets.

For more information visit www.effrx.com.